FH and cancer: In BC, we examined 9163 primary and metastatic samples from twelve studies (Table 1) and found mean prevalence rates for FH mutations of 0.36% (95% CI: 0.29–0.43% across 13 studies), significantly below the pan-cancer prevalence mean (one-sample t-test, t(12) = −5.4, p < 0.001), 1.72% for CNA deletions, and 1.13% for 1q arm loss.